Travere Therapeutics's top three insider shareholders as of April 17, 2026 are Eric M Dube (Chief Executive Officer, 432.89K shares), Steve Aselage (Chief Executive Officer, 146.92K shares), Peter Heerma (Chief Commercial Officer, 138.61K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Eric M Dube | Chief Executive Officer | 432,886 | 0 | 15 Apr, 2026 |
| Steve Aselage | Chief Executive Officer | 146,919 | 0 | 12 May, 2022 |
| Peter Heerma | Chief Commercial Officer | 138,608 | 0 | 15 Apr, 2026 |
| William E. Rote | Chief Research Officer | 123,087 | 0 | 15 Apr, 2026 |
| Christopher R. Cline | Chief Financial Officer | 116,899 | 0 | 15 Apr, 2026 |
| Jula Inrig | Chief Medical Officer | 111,473 | 0 | 15 Apr, 2026 |
| Elizabeth E Reed | Chief Legal Officer And Gc | 105,211 | 0 | 15 Apr, 2026 |
| Jeffrey A Meckler | - | 87,500 | 0 | 16 May, 2025 |
| Gary A Lyons | - | 57,500 | 0 | 16 May, 2025 |
| Timothy Coughlin | - | 55,500 | 0 | 03 Nov, 2025 |
| Sandra Calvin | Svp, Chief Accounting Officer | 49,080 | 0 | 03 Feb, 2026 |
| Noah L. Rosenberg | Chief Medical Officer | 47,614 | 0 | 17 Aug, 2021 |
| Roy D. Baynes | - | 37,500 | 0 | 07 Apr, 2026 |
| Laura Clague | Chief Financial Officer | 35,655 | 0 | 12 May, 2022 |
| John A Orwin | - | 35,375 | 0 | 16 May, 2025 |
| Ron Squarer | - | 35,375 | 0 | 16 May, 2025 |
| Sandra Poole | - | 30,000 | 0 | 16 May, 2025 |
| Suzanne Louise Bruhn | - | 28,750 | 0 | 16 May, 2025 |
| Brinkley Ruth Williams | - | 25,750 | 0 | 16 May, 2025 |
| Steve Aselage | - | 0 | 19,500 | 03 Nov, 2021 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 13 Apr, 2026 | William E. Rote | Common Stock | A | 14,000 | $0.00 | 123,087 | D | A |
| 13 Apr, 2026 | Christopher R. Cline | Common Stock | A | 14,000 | $0.00 | 125,226 | D | A |
| 13 Apr, 2026 | Jula Inrig | Common Stock | A | 14,000 | $0.00 | 119,706 | D | A |
| 13 Apr, 2026 | Peter Heerma | Common Stock | A | 14,000 | $0.00 | 145,823 | D | A |
| 13 Apr, 2026 | Elizabeth E Reed | Common Stock | A | 14,000 | $0.00 | 119,211 | D | A |
| 13 Apr, 2026 | Eric M Dube | Common Stock | A | 64,000 | $0.00 | 496,886 | D | A |
| 15 Apr, 2026 | Eric M Dube | Common Stock | D | 56,815 | $41.01 | 440,071 | D | S |
| 14 Apr, 2026 | Jula Inrig | Common Stock | D | 7,215 | $41.93 | 112,491 | D | S |
| 14 Apr, 2026 | Elizabeth E Reed | Common Stock | A | 10,000 | $19.08 | 129,211 | D | M |
| 14 Apr, 2026 | Peter Heerma | Common Stock | D | 7,215 | $41.93 | 138,608 | D | S |
| 13 Apr, 2026 | Christopher R. Cline | Common Stock | D | 65 | $28.85 | 125,161 | D | S |
| 15 Apr, 2026 | Jula Inrig | Common Stock | D | 1,018 | $42.61 | 111,473 | D | S |
| 15 Apr, 2026 | Eric M Dube | Common Stock | D | 7,165 | $41.75 | 432,906 | D | S |
| 14 Apr, 2026 | Elizabeth E Reed | Common Stock | A | 20,000 | $17.96 | 149,211 | D | M |
| 14 Apr, 2026 | Christopher R. Cline | Common Stock | D | 9 | $41.07 | 125,152 | D | S |
| 14 Apr, 2026 | Elizabeth E Reed | Common Stock | A | 7,500 | $15.46 | 156,711 | D | M |
| 15 Apr, 2026 | Eric M Dube | Common Stock | D | 20 | $42.66 | 432,886 | D | S |
| 14 Apr, 2026 | Christopher R. Cline | Common Stock | D | 7,239 | $41.93 | 117,913 | D | S |
| 14 Apr, 2026 | Elizabeth E Reed | Common Stock | D | 37,500 | $41.07 | 119,211 | D | S |
| 15 Apr, 2026 | Christopher R. Cline | Common Stock | D | 1,014 | $42.61 | 116,899 | D | S |